Lifting the veil on prices is key to lowering healthcare costs

Readily available procedure pricing may be the key to reducing healthcare costs in the country, according to new research from the University of Michigan Ann Arbor (UM).

Price transparency in healthcare is a hotly debated topic and just recently, CMS announced its eMedicare Initiative that aims to provide beneficiaries with cost and quality information. Under eMedicare, patients can take advantage of the price transparency tools to compare national average costs of certain procedures. The Trump administration has also pushed for price transparency, requiring hospitals to post prices online and potentially forcing pharmaceutical companies to publish prices in TV advertisements. 

Zach Brown, PhD, assistant professor of economics at UM, sought to study the impact of the availability of pricing information before procedures—specifically within imaging. The average prices of an MRI and CT scans in the United States are $1,200 and $228––more than double the amount in other developed countries.  

“While the price of healthcare procedures varies widely across medical providers, these prices are often difficult for patients to observe,” Brown said in a prepared statement issued by UM. “Consequently, individuals often choose providers without comparing prices.”

Brown examined how a state-run website, HealthCost, that provided information about out-of-pocket costs for a number of imaging procedures in New Hampshire would impact medical imaging visits. Privately insured individuals had access to the site.

The HealthCost website reduced the cost of medical imaging procedures 5 percent for patients and 4 percent for insurers, equaling to a savings of $7.9 million for individuals and $36 million for insurers over a five-year period. By the 5th year, out-of-pocket prices were 11 percent lower for patients. 

“If healthcare is to be left to market forces, then I believe that those markets should be transparent and competitive,” Brown said. “Reining in health care costs will require bold solutions that lift the veil on prices.”

While such a model works for imaging and perhaps other less complicated procedures, it’s important to note price transparency tools may not be as effective on procedures, including surgeries, that have prices which are determined individually.

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.